Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...

Good afternoon, everybody. I'm Chris Schott at JPMorgan and it's my pleasure to be hosting this fireside chat today with Dave Ricks, Chairman and CEO of Eli Lilly. It's been a tremendous few years ...

What will Eli Lilly do with all its cash from Mounjaro and Zepbound? What does CEO Dave Ricks think it would take for the company to reach a $1 trillion market capitalization? And how does Ricks ...

The latest declines in Eli Lilly's stock price occurred in response to management's presentation at the annual JPMorgan Healthcare conference. On Jan. 14, CEO David Ricks told investors that 2024 ...

CEO David Ricks said the company expects to produce 60% more doses of the drugs in the first half of 2025 compared to last year. Eli Lilly (LLY) shares tumbled Tuesday after the drugmaker lowered ...

That, in addition to lower-than-expected channel inventory at year-end, contributed to our Q4 results,” said Eli Lilly Chair and CEO David A. Ricks. “We continued to make progress on our ...

The only stock to drag more on the market was Eli Lilly, which fell 6.6% after saying it expects to report weaker revenue for the last three months of 2024 than previously forecast. CEO David Ricks ...

citing Eli Lilly's CEO David Ricks. Drugmakers will ask US government to pause drug price negotiations, Bloomberg News reports U.S. drugmaker Pfizer is going "all in" to develop its experimental ...